AbbVie (ABBV)

Company ID: 41 | CIK: 0001551152
10-Q view:
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
Segments are charted by their disclosed metrics (revenue, segment profit, etc.). Each line is a single segment. Reconciliation/corporate items are excluded. Major customers are shown as a percentage of revenue. Operational KPIs are grouped by metric concept; sub-metrics appear as separate lines.

Geographic Segments

No 10-Q data

Business Unit / Product Segments

Major Customers (% of Revenue)

Operational KPIs

Stockholders of record (customers)

No 10-Q data

Countries served (customers_served)

No 10-K data

Employees (headcount)

Acquisition value (other)

No 10-K data

AndroGel U.S. market share (other)

No 10-Q data

AndroGel market share (other)

No 10-K data

Clinical development programs (other)

No 10-Q data

Clinical pipeline programs (other)

No 10-Q data

Common shares outstanding (other)

Compounds in clinical development (other)

Countries marketed (other)

No 10-K data

Countries of operation (other)

No 10-Q data

Countries served (other)

Countries with marketed medicines (other)

No 10-K data

Countries with product sales (other)

Countries with sales (other)

No 10-Q data

Creon market share (other)

Dividend per share (other)

No 10-K data

Effective tax rate (other)

No 10-K data

Governmental receivables (other)

No 10-K data

Gross margin (other)

No 10-K data

HUMIRA approval markets (other)

No 10-Q data

HUMIRA approved indications (other)

No 10-K data

HUMIRA approved markets (other)

No 10-Q data

HUMIRA indications (other)

No 10-K data

HUMIRA indications EU (other)

No 10-K data

HUMIRA indications US (other)

No 10-K data

HUMIRA net sales concentration (other)

No 10-K data

HUMIRA revenue concentration (other)

HUMIRA revenue share (other)

HUMIRA sales growth (other)

No 10-K data

HUMIRA sales percentage (other)

No 10-Q data

HUMIRA sales share (other)

No 10-Q data

HUMIRA share of net revenues (other)

HUMIRA share of net sales (other)

HUMIRA share of total sales (other)

No 10-Q data

Humira revenue concentration (other)

No 10-K data

Humira revenue share (other)

Humira share of net revenues (other)

No 10-K data

IMBRUVICA clinical trials (other)

No 10-K data

Late-stage pipeline (other)

No 10-Q data

Late-stage pipeline programs (other)

No 10-Q data

Lipid franchise sales decline (other)

No 10-K data

Litigation accrual (other)

No 10-K data

Market share (other)

Mid- and late-stage pipeline programs (other)

Mid- and late-stage programs (other)

Mid-late stage programs (other)

No 10-K data

Mid/late-stage pipeline programs (other)

No 10-K data

Mid/late-stage programs (other)

No 10-K data

Net revenue growth (other)

No 10-K data

Net revenues by product (other)

No 10-K data

Net sales (other)

No 10-K data

Net sales growth (other)

No 10-K data

Operating countries (other)

No 10-Q data

Operating margin (other)

No 10-K data

Pending breast implant lawsuits (other)

No 10-K data

Pending opioid lawsuits (other)

No 10-K data

Pipeline compounds (other)

Pipeline compounds Phase II/III (other)

Pipeline compounds Phase III/registration (other)

No 10-K data

Pipeline compounds in Phase 2/3 (other)

Pipeline compounds in Phase II/III (other)

No 10-Q data

Pipeline compounds in clinical development (other)

No 10-Q data

Pipeline late-stage programs (other)

No 10-K data

Pipeline mid-late stage (other)

No 10-K data

Pipeline programs (other)

Pipeline programs in development (other)

No 10-K data

Pollution control capex (other)

No 10-Q data

Pollution control capital expenditures (other)

No 10-Q data

Pollution control expenditures (other)

No 10-Q data

Pollution control operating expenditures (other)

No 10-Q data

Pollution control opex (other)

No 10-Q data

Product sales share (other)

No 10-Q data

Public float (other)

No 10-Q data

Public float value (other)

No 10-Q data

Quarterly dividend per share (other)

No 10-K data

R&D as percent of net sales (other)

No 10-Q data

R&D expense as percent of net sales (other)

No 10-Q data

R&D expense ratio (other)

No 10-K data

Ratio of earnings to fixed charges (other)

No 10-K data

Rebates and chargebacks (other)

No 10-Q data

Remaining buyback authorization (other)

No 10-K data

Remaining repurchase authorization (other)

No 10-K data

Remaining stock repurchase authorization (other)

No 10-K data

Research and development spend (other)

No 10-Q data

Revenue growth (other)

No 10-K data

SG&A expense ratio (other)

No 10-K data

Shareholders of record (other)

No 10-Q data

Shares outstanding (other)

No 10-K data

Shares repurchased (other)

Stock repurchase authorization remaining (other)

No 10-K data

Stockholders of record (other)

No 10-Q data

Term loan facility (other)

No 10-K data

Top product revenue share (other)

No 10-Q data

Underrepresented populations (other)

No 10-Q data

Underrepresented workforce share (other)

No 10-Q data

Weighted-average diluted shares (other)

No 10-K data

Wholesale customer concentration (other)

No 10-K data

Wholesale distributor concentration (other)

No 10-Q data

Wholesaler AR concentration (other)

No 10-K data

Wholesaler accounts receivable concentration (other)

No 10-K data

Wholesaler concentration (other)

No 10-K data

Wholesaler inventory levels (other)

No 10-K data

Wholesaler share of receivables (other)

No 10-K data

Women in management (other)

No 10-Q data

Workforce diversity (other)

No 10-Q data

Worldwide net revenue growth (other)

No 10-K data

Facilities (properties)

No 10-Q data

Floor space (square_footage)

No 10-Q data
Human capital disclosures. Workforce totals and demographics are point-in-time. Flow metrics use the year-to-date period for 10-Q and full year for 10-K. Workforce actions (RIFs, restructurings, acquisition-related changes) are listed in the table at the bottom.

Workforce Totals

Demographics

No 10-Q data
No 10-Q data

Workforce Breakdowns

No breakdown data found.

HCM Metrics — Point-in-Time

No point-in-time HCM metrics found.

HCM Metrics — Flow (Annual / YTD)

No flow HCM metrics found.

Workforce Actions

Period EndTypeStatusAffected% WorkforceAnnouncedExpected CompletionGeographySegment / FunctionChargeSourceNote
2025-12-31restructuringcompletedCost of products sold, research and development, and selling, general and administrativeUSD 282 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2025 aggregate of individual plans, none individually significant; primarily employee severance and contractual obligations; restructuring reserve balance was $314 million at December 31, 2025 with no completion timeline disclosed
2025-12-31restructuringcompletedUSD 3 (billions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Cumulative charges through fiscal year 2023; plan substantially complete as of December 31, 2023; remaining accrual insignificant at December 31, 2025
2025-12-31restructuringin_progressNot specifiedNot specifiedUSD 282 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2025 charges of $282M, primarily employee severance and contractual obligations, recorded across cost of products sold, R&D and SG&A; no individual plan deemed significant and no employees-affected count disclosed. Accrued restructuring balance was $314M at 2025-12-31, indicating the program remains open.
2025-12-31acquisition_additioncompleted2025-01-232025-01-23United StatesImmunology R&Dbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Business combination completed 2025-01-23; aggregate purchase price $288M. No headcount added disclosed.
2025-12-31acquisition_additioncompleted2025-082025-08United StatesImmunology R&Dbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Asset acquisition completed August 2025; cash consideration $2.1B ($1.9B net of cash) expensed to acquired IPR&D and milestones. No headcount added disclosed.
2025-12-31acquisition_additioncompleted2025-102025-10United StatesNeuroscience R&Dbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Asset acquisition completed October 2025; $906M upfront cash payment expensed to acquired IPR&D and milestones. Lead program retained; remaining employees and programs spun off to a separate independent entity. No headcount added disclosed.
2025-12-31restructuringin_progressGlobalVariousUSD 282 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges primarily related to employee severance and contractual obligations. No individual plans were significant.
2025-12-31restructuringcompletedGlobalVariousUSD 282 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charges primarily related to employee severance and contractual obligations. No individual plans were significant.
2025-09-30restructuringin_progressUSD 36 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $36 million for the three months ended September 30, 2025; no plans individually significant; charges recognized in cost of products sold, R&D and SG&A
2025-09-30restructuringin_progressUSD 189 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $189 million for the nine months ended September 30, 2025; no plans individually significant; restructuring reserve balance $240 million at September 30, 2025
2025-09-30restructuringin_progressNot specifiedManufacturing, R&D, commercial infrastructure and administrative operationsUSD 189 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		No individually significant plans as of 2025-09-30; no employee counts disclosed. Charges were $36M in Q3 2025 and $189M YTD 2025 (vs $30M/$94M prior year). Restructuring reserve: $236M at 2024-12-31, $77M charges, $(73)M payments, $240M at 2025-09-30.
2025-09-30acquisition_additioncompletedNot specifiedR&D — in vivo targeted lipid nanoparticle anti-CD19 CAR-T (CPTX2309/ABBV-619)USD 2,100 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Completed August 2025; cash consideration $2.1B ($1.9B net of cash) expensed as acquired IPR&D. No headcount added disclosed. Also recorded $187M cash-settled post-closing employee incentive/compensation expense.
2025-09-30acquisition_additionannouncedNot specifiedR&D — bretisilocin (GM-2505), Phase 2 major depressive disorderUSD 900 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Completed subsequent to 2025-09-30; $900M upfront cash plus up to $300M development milestones. Accounting impact begins Q4 2025. No headcount added disclosed; Gilgamesh spun off a separate entity retaining most employees.
2025-09-30restructuringin_progressUSD 36 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recognized in cost of products sold, R&D, and SG&A. No individual plans were significant.
2025-09-30restructuringin_progressUSD 189 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD charges recognized in cost of products sold, R&D, and SG&A. No individual plans were significant.
2025-06-30restructuringin_progressCost of products sold, R&D and SG&AUSD 136 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $136 million for the three months ended June 30, 2025; no plans individually significant and no employee counts disclosed. Restructuring reserve balance was $241 million at June 30, 2025.
2025-06-30restructuringin_progressCost of products sold, R&D and SG&AUSD 153 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $153 million for the six months ended June 30, 2025; no employee counts disclosed.
2025-06-30restructuringin_progressNot specifiedMultiple (charges recorded in cost of products sold, R&D and SG&A based on affected employees or operations)USD 153 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended June 30, 2025 restructuring charges of $153M ($136M in Q2); no plan individually significant and no employee counts disclosed. Restructuring reserve accrued balance was $241M at 2025-06-30 (reserve roll-forward shows $46M of charges for the six months, a narrower measure than the $153M income-statement charge).
2025-06-30acquisition_additioncompleted2025-01-232025-01-23Not specifiedImmunology discovery (oral peptide IL23R inhibitor program)USD 288 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Aggregate purchase price $288M ($210M cash upfront plus $78M contingent consideration); no headcount added disclosed.
2025-06-30acquisition_additionannounced2025-06-302025-12-31Not specifiedImmunology (in vivo targeted lipid nanoparticle anti-CD19 CAR-T program)USD 2,100 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement entered June 2025; upfront cash payment of approximately $2.1B, expected to close in 2025 subject to regulatory approvals. No headcount added disclosed; announcement date shown as quarter-end month (exact day not stated).
2025-06-30restructuringin_progressUSD 153 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Filer reports $153 million in restructuring charges for the six months ended June 30, 2025, related to optimizing manufacturing, R&D, commercial infrastructure, and administrative costs. No specific employee counts were disclosed.
2025-03-31acquisition_additioncompleted2025-01-23Immunology discoveryUSD 288 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of oral peptide therapeutics biotech completed January 23, 2025; $210M upfront cash plus $78M contingent consideration fair value; no headcount figures disclosed
2025-03-31restructuringin_progressUSD 17 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing optimization of manufacturing, R&D, commercial and administrative operations; no plans individually significant and no employee counts disclosed; restructuring reserve balance $230M at March 31, 2025
2025-03-31restructuringin_progressNot disclosedNot disclosedUSD 17 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $17 million in Q1 2025 recorded across COGS, R&D and SG&A; filing states no individual plan was individually significant and discloses no employee counts. Restructuring reserve accrued balance was $230 million at 2025-03-31.
2025-03-31acquisition_additioncompleted2025-01-23United StatesImmunology (oral peptide therapeutics R&D)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed 2025-01-23 for $288 million aggregate purchase price; business combination footnote discloses no headcount added.
2025-03-31restructuringin_progressUSD 17 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recorded in cost of products sold, R&D, and SG&A. No individual plans were significant.
2024-12-31restructuringcompletedUSD 189 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		No individually significant restructuring plans in 2024; charges stem from ongoing operational optimization and were primarily employee severance and contractual obligations. Severance reserve roll-forward for 2024 shows charges of $168M, payments of $128M, and $236M accrued at year-end; the narrative $189M total likely includes non-severance contractual obligations. Filer did not disclose the number of employees affected.
2024-12-31restructuringin_progressGlobalMultiple (cost of products sold, R&D, SG&A)USD 189 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2024 charges of $189M, primarily employee severance and contractual obligations; no plans individually significant and no employee counts disclosed. Restructuring accrual was $236M at year-end.
2024-12-31acquisition_additioncompleted2024-02-12GlobalOncologybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of ImmunoGen completed 2024-02-12 for $9.8B consideration; acquired headcount not disclosed.
2024-12-31acquisition_additioncompleted2024-08-01GlobalNeurosciencebusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Cerevel Therapeutics completed 2024-08-01 for $8.7B consideration; acquired headcount not disclosed.
2024-12-31acquisition_additionannouncedGlobalImmunology (R&D)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Nimble Therapeutics acquisition closed after 2024-12-31 with ~$200M upfront cash; accounting impact begins Q1 2025. Headcount not disclosed.
2024-12-31restructuringcompletedGlobalVariousUSD 189 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Restructuring charges of $189 million recorded in 2024, primarily related to employee severance and contractual obligations. No specific headcount reduction disclosed.
2024-12-31restructuringcompletedGlobalVariousUSD 189 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charges primarily related to employee severance and contractual obligations. No individual plans were significant.
2024-09-30acquisition_additioncompleted2024-02-12Oncologybusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		ImmunoGen acquisition completed February 12, 2024; headcount added not quantified. AbbVie issued 0.3 million RSUs to ImmunoGen equity award holders
2024-09-30acquisition_additioncompleted2024-08-01Neurosciencebusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cerevel Therapeutics acquisition completed August 1, 2024; headcount added not quantified. AbbVie issued 0.3 million RSUs to Cerevel equity award holders
2024-09-30restructuringin_progressUSD 30 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $30 million for the three months and $94 million for the nine months ended September 30, 2024; no plans individually significant and no employee counts disclosed
2024-09-30restructuringin_progressGlobalManufacturing, R&D, commercial and administrative operationsUSD 94 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		YTD charge of $94M ($30M in Q3); filer states no individual plan was significant and discloses no employee counts. Restructuring reserve balance was $161M at 2024-09-30.
2024-09-30acquisition_additioncompleted2024-02-122024-02-12GlobalOncologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition closed 2024-02-12; no headcount added disclosed. Includes $349M cash-settled post-closing employee incentive expense YTD.
2024-09-30acquisition_additioncompleted2024-08-012024-08-01GlobalNeurosciencebusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition closed 2024-08-01; no headcount added disclosed. Includes $161M cash-settled post-closing employee incentive expense in Q3.
2024-09-30acquisition_additionannounced2024-10-28GlobalNeuroscience (Alzheimer's disease program)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitary agreement announced 2024-10-28 for ~$1.4B upfront cash; closing subject to regulatory approvals. No headcount disclosed.
2024-09-30restructuringin_progressUSD 30 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring charges of $30 million recorded for the three months ended Sept 30, 2024. No employee count disclosed.
2024-09-30restructuringin_progressUSD 94 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring charges of $94 million recorded for the nine months ended Sept 30, 2024. No employee count disclosed.
2024-06-30acquisition_additioncompleted2024-02-12Oncologybusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		ImmunoGen acquisition completed February 12, 2024; headcount added not disclosed. Included $349 million of cash-settled post-closing expense for ImmunoGen employee incentive awards
2024-06-30acquisition_additioncompleted2024-08-01NeuroscienceUSD 9 (billions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Cerevel Therapeutics acquisition completed August 1, 2024 for approximately $8.7 billion; headcount added not disclosed
2024-06-30restructuringin_progressUSD 49 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $49 million for the three months and $64 million for the six months ended June 30, 2024; no plans individually significant and no employee counts disclosed
2024-06-30restructuringin_progressUSD 64 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $49M in Q2 2024 and $64M YTD 2024; reserve roll-forward shows $63M of charges for the six months. Filer states no individual plan was significant and discloses no employee counts or completion dates.
2024-06-30acquisition_additioncompleted2024-02-12United StatesOncologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of ImmunoGen, Inc. closed 2024-02-12 for $9.8B consideration; no headcount added disclosed. Related $349M cash-settled post-closing employee incentive expense recorded in H1 2024.
2024-06-30acquisition_additioncompleted2024-08-01United StatesNeurosciencesubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent-event acquisition of Cerevel Therapeutics completed 2024-08-01 for approximately $8.7B; initial purchase accounting incomplete and no headcount added disclosed. Results consolidate beginning Q3 2024.
2024-06-30restructuringin_progressUSD 64 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Filer reports $64 million in restructuring charges for the six months ended June 30, 2024. No specific employee counts or completion dates were disclosed for these current-period charges.
2024-03-31acquisition_additioncompleted2024-02-12OncologyUSD 349 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		ImmunoGen acquisition completed February 12, 2024; headcount added not quantified. Includes $349 million of cash-settled post-closing expense for ImmunoGen employee incentive awards
2024-03-31restructuringin_progressUSD 15 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing optimization plans not individually significant; no employee counts disclosed. Restructuring reserve balance $178 million at March 31, 2024
2024-03-31acquisition_additioncompleted2024-02-122024-02-12GlobalOncologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		ImmunoGen headcount added not disclosed; 0.3 million RSUs issued to ImmunoGen equity holders and $349M cash-settled post-closing employee incentive expense recorded in Q1 2024.
2024-03-31restructuringin_progressGlobalMultiple (cost of products sold, R&D, SG&A)USD 15 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $15M in Q1 2024; filer states no individual plans were significant as of March 31, 2024 and no employee counts disclosed. Restructuring accrual rolled from $196M to $178M.
2024-03-31restructuringin_progressUSD 15 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring charges of $15 million recorded for the three months ended March 31, 2024. No individual plans were significant. Charges recorded in cost of products sold, R&D, and SG&A.
2023-12-31restructuringcompletedUSD 132 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Aggregate of individually insignificant periodic plans recorded during FY2023; costs primarily employee severance and contractual obligations, booked across cost of products sold, R&D and SG&A. Severance reserve roll-forward shows $107M of charges and a $196M ending balance at year-end.
2023-12-31restructuringin_progressUSD 288 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2023 charges under the multi-year cost-reduction and integration plan launched after the 2020 Allergan acquisition; costs include severance, retention and other termination benefits. Cumulative charges reached $2.5B through 2023; reserve balance $43M at year-end. Headcount affected not disclosed.
2023-12-31restructuringin_progressGlobalManufacturing, R&D, commercial, administrative operationsUSD 132 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $132 million in 2023 primarily related to employee severance and contractual obligations; no individual plan was individually significant and no employee count was disclosed
2023-12-31restructuringin_progressGlobalAllergan integrationUSD 288 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2023 charges of $288 million (COGS $89M, R&D $7M, SG&A $192M) for severance, retention and other integration expenses; cumulative charges of $2.5 billion through 2023; no employee count disclosed for 2023 activity
2023-12-31acquisition_additioncompleted2024-02-122024-02-12GlobalOncologyUSD 10,100 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent event: acquisition completed February 12, 2024 for approximately $10.1 billion; no headcount disclosed; initial accounting not complete at filing date
2023-12-31acquisition_additionannounced2023-12-06GlobalNeuroscienceUSD 8,700 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement announced December 6, 2023 at $45.00 per share, total value approximately $8.7 billion; expected to close in 2024; no headcount disclosed
2023-12-31restructuringcompletedGlobalAllergan IntegrationUSD 288 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges of $288 million recorded in 2023 related to the Allergan integration plan, consisting of severance and employee benefit costs and other integration expenses. Cumulative charges through 2023 were $2.5 billion.
2023-12-31restructuringin_progressGlobalVariousUSD 132 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Restructuring charges recorded were $132 million in 2023, primarily related to employee severance and contractual obligations. No plans were individually significant.
2023-12-31restructuringin_progressGlobalVariousUSD 288 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charges associated with the Allergan acquisition integration plan totaled $288 million in 2023, consisting of severance, employee benefits, and other integration expenses.
2023-09-30restructuringin_progressUSD 60 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Allergan integration plan charges of $60 million for the three months and $202 million for the nine months ended September 30, 2023; cumulative charges of $2.5 billion through September 30, 2023. Charges consist of severance, employee benefit costs and other integration expenses. No employee count disclosed.
2023-09-30restructuringin_progressUSD 10 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Other restructuring charges of $10 million for the three months and $55 million for the nine months ended September 30, 2023; restructuring reserve balance of $143 million at September 30, 2023. No employee count disclosed.
2023-09-30restructuringin_progressUSD 202 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charges shown are for the nine months ended 2023-09-30 (Q3: $60M). Cumulative charges of $2.5B since the Allergan acquisition closing; accrued liability balance of $41M at 2023-09-30 after $192M of charges and $258M of payments. No employee counts disclosed; charges comprise severance, employee benefits and other integration expenses.
2023-09-30restructuringin_progressUSD 55 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charges shown are for the nine months ended 2023-09-30 (Q3: $10M). Restructuring reserve roll-forward shows $31M of charges and $64M of payments YTD, leaving a $143M accrued balance at 2023-09-30. No employee counts or completion dates disclosed.
2023-09-30restructuringin_progressUSD 60 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Allergan Integration Plan charges for three months ended Sept 30, 2023 include severance and other integration expenses.
2023-09-30restructuringin_progressUSD 202 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Allergan Integration Plan charges for nine months ended Sept 30, 2023 include severance and other integration expenses.
2023-09-30restructuringin_progressUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Other Restructuring charges for three months ended Sept 30, 2023.
2023-09-30restructuringin_progressUSD 55 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Other Restructuring charges for nine months ended Sept 30, 2023.
2023-06-30restructuringin_progressUSD 84 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Allergan integration plan charges of $84 million for the three months ended June 30, 2023, comprising severance, employee benefit and other integration costs; cumulative charges of $2.4 billion through June 30, 2023. No employee counts disclosed.
2023-06-30restructuringin_progressUSD 18 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Other restructuring charges of $18 million for the three months ended June 30, 2023; restructuring reserve balance of $149 million at June 30, 2023. No employee counts disclosed.
2023-06-30restructuringin_progressGlobalAllergan acquisition integrationUSD 142 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended 2023-06-30 charges (Q2 alone: $84M); cumulative charges of $2.4B through 2023-06-30. No employee counts disclosed; accrual balance $47M at 2023-06-30
2023-06-30restructuringin_progressGlobalOther restructuringUSD 45 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended 2023-06-30 charges (Q2 alone: $18M); no employee counts disclosed; reserve balance $149M at 2023-06-30
2023-06-30restructuringin_progressUSD 142 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Allergan Integration Plan: Total charges of $142 million for the six months ended June 30, 2023, consisting of severance, employee benefits, and other integration expenses. No specific headcount affected is disclosed.
2023-06-30restructuringin_progressUSD 45 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Other Restructuring: Charges of $45 million for the six months ended June 30, 2023. No specific headcount affected is disclosed.
2023-03-31restructuringin_progressUSD 27 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $27 million for the quarter; no employee counts disclosed. Restructuring reserve balance of $169 million at March 31, 2023.
2023-03-31restructuringin_progressUSD 58 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Integration charges of $58 million in Q1 2023 (severance, retention and other integration expenses); cumulative charges of $2.3 billion through March 31, 2023. No employee counts disclosed.
2023-03-31restructuringin_progressGlobalAll functions (Allergan acquisition integration)USD 58 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2023 charges of $58M (COGS $14M, SG&A $44M); cumulative charges of $2.3B through 2023-03-31. No employee count disclosed; accrued balance $96M at quarter end
2023-03-31restructuringin_progressGlobalOther restructuring programsUSD 27 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Narrative states $27M restructuring charges for Q1 2023; reserve roll-forward table shows $17M charges with $169M accrued balance at quarter end. No employee count disclosed
2023-03-31restructuringin_progressUSD 58 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges associated with the Allergan acquisition integration plan. Includes severance and other integration expenses. No employee count disclosed.
2023-03-31restructuringin_progressUSD 27 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Other restructuring charges recorded. No employee count disclosed.
2022-12-31restructuringcompleted2020-05-08GlobalCompany-wide (single global business segment)USD 2 (billions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Allergan Integration Plan implemented following the May 2020 Allergan acquisition close. Charge is cumulative through fiscal year-end (2020–2022), bundling severance/employee benefits and other integration expenses; affected headcount not disclosed. Filer states cost-synergy objectives were successfully executed, with $2.5 billion of annual cost synergies realized in 2022.
2022-12-31restructuringcompletedUSD 241 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Fiscal 2022 restructuring charges primarily for employee severance and contractual obligations; no individual plans were significant and affected headcount not disclosed. Charges recorded in cost of products sold, R&D, and SG&A.
2022-12-31restructuringin_progress2020-05-08GlobalAllergan integration (combined organization)USD -8 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2022 severance and employee benefit charges were a net benefit of $8M; other integration charges were $547M in FY2022. Cumulative charges of $2.3B through 2022 since the May 8, 2020 acquisition close; accrued balance of $107M remained at year-end. No employee counts disclosed. Company realized $2.5B of annual cost synergies in 2022.
2022-12-31restructuringin_progressGlobalManufacturing, R&D, commercial and administrative operationsUSD 241 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2022 restructuring charges of $241M, primarily employee severance and contractual obligations; no individual plan was individually significant. Restructuring reserve balance of $176M at December 31, 2022. No employee counts or announcement dates disclosed.
2022-12-31acquisition_additioncompleted2022-10-01GlobalResearch & Development (DJS-002 / HEPTAD platform)USD 287 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed October 2022; aggregate purchase price $287M ($255M cash upfront plus $32M contingent consideration fair value). Headcount added not disclosed; announcement month stated, exact date not given.
2022-12-31divestiture_reductioncompleted2022-06-01GlobalOther Key Products (Pylera mature brand)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		June 2022 sale of worldwide commercial rights to Pylera; net cash proceeds $215M and pre-tax gain of $172M. Headcount removed not disclosed; month stated, exact date not given.
2022-12-31restructuringin_progress2020-05-08GlobalAllergan IntegrationUSD 2,300 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Total cumulative charges of $2.3 billion through 2022 for Allergan integration plan. 2022 charges were a net benefit of $8 million.
2022-12-31restructuringcompleted2022-01-012022-12-31GlobalOther RestructuringUSD 241 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges recorded in 2022 primarily related to employee severance and contractual obligations.
2022-12-31restructuringin_progressGlobalAllergan IntegrationUSD 2,300 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Total cumulative charges of $2.3 billion through 2022 for Allergan integration plan, consisting of severance and employee benefit costs and other integration expenses.
2022-12-31restructuringcompletedGlobalOther RestructuringUSD 241 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Restructuring charges recorded were $241 million in 2022, primarily related to employee severance and contractual obligations.
2022-09-30restructuringin_progress2022-12-31USD 143 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Other restructuring charges of $50 million for the three months and $143 million for the nine months ended September 30, 2022; no employee counts disclosed. Restructuring reserve balance of $120 million at September 30, 2022.
2022-09-30restructuringin_progress2022-12-31USD 327 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Allergan integration charges of $327 million for the nine months ended September 30, 2022 (severance and employee benefits plus other integration); total cumulative charges of approximately $2 billion expected through 2022. No employee counts disclosed.
2022-09-30restructuringin_progress2022-12-31GlobalAllergan integrationUSD 111 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2022 charges of $111M (severance $5M, other integration $106M); YTD charges $327M. Program targets ~$2B cumulative charges through 2022 and ~$2.5B annual cost synergies; no employee counts disclosed.
2022-09-30restructuringin_progressGlobalOther restructuringUSD 50 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2022 restructuring charges of $50M; YTD $143M. Restructuring reserve balance $120M at 2022-09-30; no employee counts disclosed.
2022-09-30divestiture_reductioncompleted2022-06-302022-06-30GlobalGastroenterology (Pylera brand)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of worldwide commercial rights to Pylera completed June 2022; net cash proceeds $215M, pre-tax gain $172M. No headcount associated with the divestiture disclosed.
2022-09-30acquisition_additioncompleted2022-02-282022-02-28BelgiumNeuroscience (synaptic vesicle protein 2A modulators)USD 130 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Asset acquisition completed February 2022; $130M upfront expensed as acquired IPR&D, up to $870M in future milestones. No headcount added disclosed.
2022-09-30acquisition_additionannounced2022-09-30GlobalFibrotic diseases (DJS-002 / HEPTAD platform)USD 255 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement entered into after 2022-09-30; ~$255M upfront plus up to $95M milestones. No headcount added disclosed.
2022-09-30restructuringin_progress2022-12-31GlobalAllergan IntegrationUSD 2,000 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Allergan Integration Plan expects total cumulative charges of approximately $2 billion through 2022, consisting of severance, employee benefits, and other integration expenses.
2022-09-30restructuringin_progressGlobalOther RestructuringUSD 143 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Other restructuring charges of $143 million recorded for the nine months ended September 30, 2022.
2022-06-30restructuringin_progress2022-12-31USD 2,000 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Allergan integration plan; total cumulative charges of approximately $2 billion through 2022 covering severance, employee benefits and other integration expenses. No employee counts disclosed. Six months ended June 30, 2022 charges: $216 million other integration and $(3) million severance and employee benefits.
2022-06-30restructuringin_progressUSD 93 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Other restructuring charges of $36 million for the three months and $93 million for the six months ended June 30, 2022; no employee counts disclosed.
2022-06-30restructuringin_progress2022-12-31GlobalAllergan acquisition integration (enterprise-wide)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		No employee counts disclosed. Six months ended June 30, 2022: severance and employee benefit charges of $(3) million (net benefit) and other integration charges of $216 million. Total cumulative charges expected of approximately $2 billion through 2022; plan targets about $2.5 billion of annual cost synergies in 2022. Accrued balances at June 30, 2022: $129 million severance and employee benefits, $12 million other integration.
2022-06-30restructuringin_progressGlobalOther restructuringUSD 93 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		No employee counts disclosed. Restructuring charges of $93 million for the six months ended June 30, 2022 ($36 million for the three months). Restructuring reserve roll-forward for the six months: $33 million opening, $72 million charges, $(13) million payments, $92 million closing balance.
2022-06-30restructuringin_progress2022-12-31GlobalAllergan IntegrationUSD 216 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Allergan Integration Plan charges for six months ended June 30, 2022. Total cumulative charges expected to be approximately $2 billion through 2022. Employee count not disclosed.
2022-06-30restructuringin_progressGlobalOther RestructuringUSD 93 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Other Restructuring charges for six months ended June 30, 2022. Employee count not disclosed.
2022-03-31restructuringin_progress2022-12-31USD 57 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $57 million for the quarter; no employee counts disclosed. Restructuring reserve balance rose from $33 million to $72 million.
2022-03-31restructuringin_progress2022-12-31USD 110 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Allergan integration plan charges of $110 million in the quarter ($8M severance and employee benefits; $102M other integration); total cumulative charges of approximately $2 billion expected through 2022. No headcount figures disclosed.
2022-03-31acquisition_additioncompleted2022-02-01USD 130 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Syndesi Therapeutics SA accounted for as an asset acquisition; upfront payment of $130 million recorded in acquired IPR&D and milestones. No headcount figures disclosed.
2022-03-31restructuringin_progress2022-12-31GlobalAllergan integration (enterprise-wide)USD 110 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Allergan Integration Plan; Q1 2022 charges comprised $8M severance/employee benefits and $102M other integration. Cumulative charges expected to total approximately $2 billion through 2022; plan targets about $2.5 billion of annual cost synergies in 2022. Severance accrual was $208M at 2022-03-31. No employee headcount affected is disclosed.
2022-03-31restructuringin_progressGlobalOther restructuringUSD 57 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $57M recorded in Q1 2022 (prior-year comparative $38M not extracted); reserve roll-forward shows $48M charges to the reserve, ending balance $72M at 2022-03-31. No employee headcount affected is disclosed.
2022-03-31restructuringin_progress2022-12-31GlobalAllergan IntegrationUSD 110 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Allergan Integration Plan charges of $110 million ($8M severance, $102M other integration) for Q1 2022. Total cumulative charges expected to be approximately $2 billion through 2022. Employee count not disclosed.
2022-03-31restructuringin_progressGlobalOther RestructuringUSD 57 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Other restructuring charges of $57 million for Q1 2022. Employee count not disclosed.
2021-12-31restructuringin_progress2020-05-082022-12-31GlobalCompany-wide (cost of products sold, R&D, SG&A)USD 69 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year Allergan integration plan implemented following the May 8, 2020 acquisition closing. FY2021 severance and employee benefit charges were $69M (2020: $696M); total FY2021 integration charges including other integration expenses were $587M. Cumulative program charges of ~$2B expected through 2022, targeting ~$2.5B of annual cost synergies in 2022. No headcount or percentage of workforce affected disclosed.
2021-12-31restructuringcompletedCompany-wide (cost of products sold, R&D, SG&A)USD 59 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2021 restructuring charges of $59M, primarily employee severance and contractual obligations; no individual plans were significant. Charges recorded across cost of products sold, R&D and SG&A based on classification of affected employees or operations. Restructuring reserve roll-forward shows $54M of 2021 charges with $33M accrued balance at year-end. No headcount disclosed.
2021-12-31restructuringin_progress2020-05-082022-12-31GlobalCompany-wide (Allergan integration)USD 69 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2021 severance and employee benefit charges of $69M (COGS $5M, R&D $0, SG&A $64M); FY2021 other integration charges were $518M. Program totals approximately $2B of cumulative charges through 2022; employee counts not disclosed.
2021-12-31restructuringin_progressGlobalManufacturing, R&D, commercial and administrative operationsUSD 59 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2021 restructuring charges of $59M, primarily employee severance and contractual obligations; no individual plan was individually significant and employee counts were not disclosed.
2021-12-31acquisition_additioncompleted2021-12-31United StatesAesthetics (Soliton, Inc.)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed December 2021 for $535M cash consideration; acquired headcount not disclosed.
2021-12-31restructuringin_progress2020-05-082022-12-31GlobalAll segmentsUSD 2,000 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Integration plan following Allergan acquisition. Total cumulative charges of approximately $2 billion expected through 2022. Includes severance and other integration expenses.
2021-12-31restructuringin_progress2020-05-082022-12-31GlobalAll functionsUSD 587 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Allergan integration plan charges incurred in 2021: $69M severance/employee benefits and $518M other integration expenses. Total cumulative charges expected to be approx $2B through 2022.
2021-12-31restructuringcompletedGlobalVariousUSD 59 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Other restructuring charges recorded in 2021 were $59 million, primarily related to employee severance and contractual obligations.
2021-09-30restructuringin_progress2020-05-082022-12-31USD 2,000 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Allergan integration plan; total cumulative charges of approximately $2 billion expected through 2022, comprising severance and employee benefit costs and other integration expenses. No employee headcount figures disclosed. Nine months ended 2021-09-30 charges: $55 million severance/employee benefits plus $384 million other integration.
2021-09-30restructuringin_progress2020-05-082022-12-31GlobalEnterprise (R&D, SG&A, cost of products sold)USD 2,000 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Integration plan following Allergan acquisition; expected total cumulative charges of approximately $2 billion through 2022, consisting of severance/employee benefits and other integration costs. No employee headcount affected is disclosed. Nine months ended 2021-09-30 charges disclosed as $55 million severance and employee benefits and $384 million other integration.
2021-09-30restructuringin_progressGlobalNot specifiedUSD 56 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $56 million for the nine months ended 2021-09-30 ($13 million for the three months ended). No employee counts, announcement date, or completion timeline disclosed; restructuring reserve balance was $53 million at 2021-09-30.
2021-09-30acquisition_additionannounced2021-05-01United StatesAestheticsUSD 550 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement announced May 2021 to acquire Soliton at $22.60 per share, enterprise value approximately $550 million; closing subject to regulatory approval. No headcount disclosed. Announcement day within month not specified in filing.
2021-09-30acquisition_additioncompleted2021-09-30United StatesHematologic OncologyUSD 400 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of TeneoOne and TNB-383B completed September 2021, accounted for as an asset acquisition; $400 million exercise payment recorded to acquired IPR&D, plus up to $250 million in milestones. No employee headcount disclosed; exact announcement/completion dates not specified.
2021-09-30restructuringin_progress2020-05-082022-12-31GlobalAllergan IntegrationUSD 2,000 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Allergan Integration Plan expects total cumulative charges of approximately $2 billion through 2022, consisting of severance, employee benefits, and other integration expenses.
2021-09-30restructuringin_progressGlobalOther RestructuringUSD 56 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Other restructuring charges of $56 million recorded for the nine months ended September 30, 2021.
2021-06-30restructuringin_progress2022-12-31USD 2 (billions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Allergan integration plan; total charges of approximately $2 billion expected through 2022, comprising severance and employee benefit costs and other integration expenses. Charges of $12 million for the three months and $35 million for the six months ended June 30, 2021. No employee counts disclosed.
2021-06-30restructuringin_progressUSD 5 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Other restructuring charges of $5 million for the three months and $43 million for the six months ended June 30, 2021. No employee counts disclosed.
2021-06-30restructuringin_progress2020-05-082022-12-31GlobalEnterprise (Allergan integration)USD 269 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total charges of approximately $2 billion expected through 2022; six months ended 2021 charges comprised $35M severance and employee benefits plus $234M other integration. No employee headcount affected disclosed. Plan implemented following Allergan acquisition closing; announcement date set to closing date as filing does not give a separate plan announcement date
2021-06-30restructuringin_progressGlobalOther restructuringUSD 43 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $43M for the six months ended June 30, 2021 ($5M in Q2); reserve balance of $69M at June 30, 2021. No employee counts, announcement date, or completion date disclosed
2021-06-30restructuringin_progress2020-05-082022-12-31GlobalAll functionsUSD 2,000 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Allergan Integration Plan: AbbVie expects to incur total charges of approximately $2 billion through 2022. Costs consist of severance, employee benefits, and other integration expenses. No specific employee count affected was disclosed in this filing.
2021-03-31restructuringin_progress2020-05-082022-12-31USD 139 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2021 charges of $23M severance/employee benefits and $116M other integration; total program charges expected at approximately $2 billion through 2022
2021-03-31restructuringin_progressUSD 38 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring reserve balance of $92 million at March 31, 2021; no employee counts disclosed
2021-03-31restructuringin_progress2022-12-31GlobalAllUSD 23 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance and employee benefits charges for Q1 2021; total plan charges of approximately $2 billion expected through 2022; no employee count disclosed. Plan implemented following the May 8, 2020 Allergan acquisition close.
2021-03-31restructuringin_progressGlobalAllUSD 38 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Other restructuring charges of $38 million recorded for the three months ended March 31, 2021; no employee count disclosed
2021-03-31restructuringin_progress2020-05-082022-12-31GlobalAll functionsUSD 2,000 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Allergan Integration Plan: AbbVie expects to incur total charges of approximately $2 billion through 2022 to reduce costs, integrate and optimize the combined organization. Costs consist of severance, employee benefits, and other integration expenses.
2020-12-31acquisition_additioncompleted2020-05-082020-05-08GlobalCompany-wide (single operating segment)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Allergan plc acquired May 8, 2020 for total consideration of $64,084 million ($39,675M cash plus $24,409M equity); the number of Allergan employees added was not separately disclosed in the filing.
2020-12-31restructuringin_progress2020-05-082022-12-31GlobalCost of products sold, Research and development, and Selling, general and administrativeUSD 696 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Implemented following the Allergan closing. 2020 charges were $696M severance and employee benefits plus $435M other integration expenses ($1,131M total); roughly $2 billion of total charges expected through 2022. Headcount affected not disclosed. Charges span COGS ($109M severance), R&D ($199M) and SG&A ($388M).
2020-12-31restructuringin_progressManufacturing, R&D, commercial infrastructure and administrative operationsUSD 60 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Recurring optimization activity; no individually significant plans in 2020. Charges primarily employee severance and contractual obligations. Reserve roll-forward shows $58M of 2020 charges and a $90M accrued balance at December 31, 2020.
2020-12-31acquisition_additioncompletedGlobalCompany-wide — immunology, hematologic oncology, aesthetics, neuroscience, eye care, women's healthbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Allergan plc completed May 8, 2020 for total consideration of $64,084 million; headcount added through the acquisition is not disclosed.
2020-12-31restructuringin_progress2022-12-31GlobalCompany-wide — severance across cost of products sold, R&D and SG&A functionsUSD 696 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2020 charges: $696M severance and employee benefits plus $435M other integration ($1,131M total). Multi-year program expected to incur approximately $2B of charges through 2022 to deliver more than $2B of annual cost synergies; employees affected not disclosed.
2020-12-31restructuringin_progressGlobalManufacturing, R&D, commercial infrastructure and administrative operationsUSD 60 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2020 restructuring charges of $60M, primarily employee severance and contractual obligations; filer states no individually significant plans were approved in 2020 and discloses no employee counts. Restructuring reserve accrued balance was $90M at December 31, 2020.
2020-12-31restructuringin_progress2020-05-082022-12-31GlobalAllergan IntegrationUSD 2,000 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		AbbVie expects to incur approximately $2 billion of charges through 2022 related to the Allergan acquisition integration plan. Charges consist of severance and employee benefit costs and other integration expenses.
2020-12-31restructuringin_progress2020-01-012020-12-31GlobalOther RestructuringUSD 60 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		In 2020, AbbVie recorded $60 million in restructuring charges primarily related to employee severance and contractual obligations.
2020-12-31restructuringin_progress2020-05-082022-12-31GlobalAll functionsUSD 2,000 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Allergan integration plan expected to incur approximately $2 billion of charges through 2022, consisting of severance and employee benefit costs and other integration expenses.
2020-12-31restructuringcompleted2020-01-012020-12-31GlobalAll functionsUSD 60 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Other restructuring charges recorded were $60 million in 2020, primarily related to employee severance and contractual obligations.
2020-09-30restructuringin_progress2020-05-082022-12-31R&D (~50%), SG&A (~40%), cost of products sold (~10%)USD 865 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Allergan integration plan targeting over $2 billion of annual cost synergies over three years; approximately $2 billion of total charges expected through 2022. Nine-month 2020 charges of $562 million severance and employee benefits plus $303 million other integration; accrued balances of $289 million and $33 million respectively at September 30, 2020. No employee count disclosed.
2020-09-30restructuringin_progressUSD 42 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Other restructuring charges of $11 million for the three months and $42 million for the nine months ended September 30, 2020; restructuring reserve balance of $93 million at quarter-end. No employee count disclosed.
2020-09-30acquisition_additioncompleted2020-05-08business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		AbbVie completed the Allergan acquisition on May 8, 2020 (total consideration $64.1 billion); Allergan workforce absorbed into consolidated headcount, though no specific headcount figure was disclosed.
2020-09-30acquisition_additioncompleted2020-05-082020-05-08GlobalAll segmentsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Allergan acquisition closed May 8, 2020; headcount added through the acquisition is not disclosed in the filing
2020-09-30restructuringin_progress2020-05-082022-12-31GlobalR&D, SG&A and cost of products soldUSD 562 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance and employee benefit charges for nine months ended September 30, 2020; an additional $303M of other integration charges in the same period; program expected to incur approximately $2B of charges through 2022 to deliver over $2B of annual cost synergies; no employee counts disclosed
2020-09-30restructuringin_progressGlobalNot specifiedUSD 42 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges for nine months ended September 30, 2020 ($11M in the quarter); restructuring reserve balance of $93M at September 30, 2020; no employee counts or announcement date disclosed
2020-09-30restructuringin_progress2020-05-082022-12-31GlobalR&D, SG&A, Cost of Products SoldUSD 2,000 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		AbbVie expects to incur approximately $2 billion of charges through 2022 for the Allergan integration plan, consisting of severance, employee benefits, and other integration expenses. No specific employee count was disclosed for the total program.
2020-06-30acquisition_additioncompleted2020-05-08GlobalAllergan plcbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Allergan acquisition completed May 8, 2020; no employee headcount added was disclosed
2020-06-30restructuringin_progress2020-05-082022-12-31GlobalR&D (~50%), SG&A (~40%), cost of products sold (~10%)USD 588 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Integration plan targeting over $2 billion annual cost synergies over three years; approximately $2 billion of charges expected through 2022. Six-month 2020 charges: $483M severance and employee benefits plus $143M other integration; no employee count disclosed
2020-06-30restructuringin_progressUSD 14 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Other restructuring charges of $14 million for the three months and $31 million for the six months ended June 30, 2020; no employee count disclosed
2020-06-30acquisition_additioncompleted2020-05-082020-05-08GlobalAll therapeutic areas (immunology, hematologic oncology, aesthetics, neuroscience, eye care, women's health)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Allergan acquisition closed May 8, 2020; total consideration $64,084 million. No headcount added disclosed in the filing.
2020-06-30restructuringin_progress2020-05-082022-12-31GlobalR&D (~50% of synergies), SG&A (~40%), cost of products sold (~10%)USD 483 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance and employee benefit charges of $483M for the three and six months ended June 30, 2020, plus $143M other integration charges YTD. Plan targets over $2 billion of annual cost synergies within three years, with roughly $2 billion of charges expected through 2022. No employee counts disclosed; accrued balance at June 30, 2020 was $348M severance and $7M other.
2020-06-30restructuringin_progressGlobalNot specifiedUSD 31 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $14M for the three months and $31M for the six months ended June 30, 2020. Reserve balance of $102M at June 30, 2020 (from $140M at December 31, 2019). No employee counts or completion dates disclosed.
2020-06-30restructuringin_progress2020-05-082022-12-31GlobalR&D, SG&A, Cost of Products SoldUSD 2,000 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		AbbVie expects to incur approximately $2 billion of charges through 2022 for the Allergan integration plan, consisting of severance, employee benefits, and other integration expenses. Specific employee counts affected are not disclosed in this filing.
2020-03-31restructuringin_progressUSD 17 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $17 million for the quarter; no employee counts disclosed. Reserve balance of $119 million at March 31, 2020 after $38 million of payments.
2020-03-31restructuringin_progressUSD 17 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $17M recorded in Q1 2020; reserve roll-forward from $140M to $119M. No employee counts, geographies, or completion dates disclosed.
2020-03-31restructuringin_progressUSD 17 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		AbbVie recorded restructuring charges of $17 million for the three months ended March 31, 2020. No employee count disclosed.
2020-03-31restructuringin_progressUSD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-12-31restructuringcompletedUSD 234 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Aggregate of individually insignificant plans approved during 2019; charges primarily related to employee severance and contractual obligations, recorded across cost of products sold, R&D and SG&A. Restructuring reserve roll-forward shows $219 million of 2019 charges, $178 million of payments and a $140 million accrued balance at December 31, 2019. No employee counts, announcement dates or completion timelines were disclosed.
2019-12-31restructuringin_progressUSD 234 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2019 restructuring charges of $234 million, primarily employee severance and contractual obligations, recorded across cost of products sold, R&D and SG&A; no individually significant plan approved and no employee-affected count disclosed. Restructuring accrual balance was $140 million at 2019-12-31, indicating the program remained open at year-end.
2019-12-31restructuringcompletedGlobalManufacturing, R&D, Commercial, AdministrativeUSD 234 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges primarily related to employee severance and contractual obligations. No individual plans were significant.
2019-12-31restructuringcompletedUSD 234 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charges primarily related to employee severance and contractual obligations. No individually significant plans.
2019-12-31restructuringin_progressEmployee Severance [Member]USD 234,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressUSD 219,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-09-30restructuringin_progressUSD 22 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $22 million for the three months ended September 30, 2019; nine-month charges of $208 million primarily related to severance costs. No employee counts disclosed.
2019-09-30restructuringin_progressUSD 208 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine months ended September 30, 2019 restructuring charges of $208 million, primarily severance costs; restructuring reserve balance of $99 million at December 31, 2018 grew to $194 million of charges less $133 million of payments, leaving $161 million accrued at September 30, 2019. No employee counts disclosed.
2019-09-30restructuringin_progressUSD 208 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $208M for nine months ended 2019-09-30 ($22M in Q3), primarily severance costs; no employee counts, geographies, or completion dates disclosed. Restructuring reserve accrued balance was $160M at 2019-09-30.
2019-09-30restructuringin_progressUSD 208 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		AbbVie recorded restructuring charges of $208 million for the nine months ended September 30, 2019, primarily related to severance costs. No specific employee count was disclosed.
2019-09-30restructuringin_progressUSD 22,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressUSD 19 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $19 million for the three months ended June 30, 2019, primarily severance costs; no employee count disclosed
2019-06-30restructuringin_progressUSD 186 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $186 million for the six months ended June 30, 2019, primarily severance costs; restructuring reserve balance of $191 million at June 30, 2019
2019-06-30restructuringin_progressUSD 186 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $19M in Q2 2019 and $186M for the six months ended June 30, 2019, primarily severance costs; no employee counts, announcement dates, or completion timing disclosed. Restructuring reserve accrued balance was $191M at June 30, 2019.
2019-06-30restructuringin_progressUSD 19 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring charges primarily related to severance costs for the three months ended June 30, 2019.
2019-06-30restructuringin_progressUSD 186 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring charges primarily related to severance costs for the six months ended June 30, 2019.
2019-06-30restructuringin_progressUSD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressUSD 167 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Charges primarily related to severance costs; no employee count disclosed. Restructuring reserve balance rose from $99 million to $209 million during the quarter.
2019-03-31restructuringin_progressUSD 167 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2019 restructuring charges of $167 million, primarily severance costs; restructuring reserve accrued balance rose from $99M to $209M. No employee count, geography, or completion date disclosed.
2019-03-31restructuringin_progressUSD 167 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring charges of $167 million recorded for the three months ended March 31, 2019, primarily related to severance costs. No employee count disclosed.
2019-03-31restructuringin_progressUSD 167,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-12-31restructuringcompletedUSD 70 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Aggregate fiscal-2018 charges across multiple small plans; none individually significant. Charges were primarily employee severance and contractual obligations. Severance reserve roll-forward shows $59M of 2018 charges and $46M paid, ending accrual $99M at December 31, 2018. No employee counts or completion timelines disclosed.
2018-12-31restructuringin_progressUSD 70 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2018 charges, primarily employee severance and contractual obligations, recorded across cost of products sold, R&D and SG&A; no employees-affected count or completion date disclosed. Restructuring accrual was $99 million at 2018-12-31.
2018-12-31restructuringcompletedGlobalManufacturing, R&D, Commercial, AdministrativeUSD 70 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges primarily related to employee severance and contractual obligations. No individually significant plans.
2018-12-31restructuringcompletedUSD 70 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charges primarily related to employee severance and contractual obligations. No individually significant plans.
2018-12-31restructuringin_progressUSD 59,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressEmployee Severance [Member]USD 70,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-09-30restructuringin_progressUSD 45 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $45M for nine months ended 2018-09-30 ($22M in Q3); reserve roll-forward disclosed but no employee counts, geographies, or completion dates given
2018-09-30restructuringin_progressUSD 22 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring charges of $22 million recorded for the three months ended September 30, 2018. No employee count disclosed.
2018-09-30restructuringin_progressUSD 45 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring charges of $45 million recorded for the nine months ended September 30, 2018. No employee count disclosed.
2018-09-30restructuringin_progressUSD 22,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $1 million for the three months ended June 30, 2018; no employee counts disclosed. Restructuring reserve balance was $88 million at June 30, 2018.
2018-06-30restructuringin_progressUSD 23 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $23 million for the six months ended June 30, 2018; no employee counts disclosed.
2018-06-30restructuringin_progressUSD 23 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $1M in Q2 2018 and $23M YTD 2018; reserve roll-forward from $86M at Dec 31, 2017 to $88M at Jun 30, 2018. No employee counts, geographies, or completion dates disclosed.
2018-06-30restructuringin_progressUSD 23 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		AbbVie recorded restructuring charges of $23 million for the six months ended June 30, 2018. No employee count was disclosed.
2018-06-30restructuringin_progressUSD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressUSD 22 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $22 million for the quarter; reserve balance rose from $86 million to $101 million after $7 million of payments. No employee counts disclosed.
2018-03-31restructuringin_progressUSD 22 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $22 million recorded for the three months ended March 31, 2018; reserve roll-forward disclosed (accrued balance $101 million at March 31, 2018) but no employee counts, geographies, or completion dates are provided
2018-03-31restructuringin_progressUSD 22 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		AbbVie recorded restructuring charges of $22 million for the three months ended March 31, 2018. No employee count disclosed.
2018-03-31restructuringin_progressUSD 22,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-12-31restructuringcompletedUSD 86 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Aggregate FY2017 restructuring charges primarily related to employee severance and contractual obligations; recorded in cost of products sold, R&D and SG&A. Filer states no individual plan was significant in 2017, so no per-action headcount or completion date disclosed. Restructuring reserve roll-forward shows $86M accrued at Dec 31, 2017.
2017-12-31restructuringin_progressUSD 86 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2017 restructuring charges of $86 million, primarily employee severance and contractual obligations; no individually significant plans approved in 2017 and no employee-affected counts or completion dates disclosed. Recorded across cost of products sold, R&D and SG&A.
2017-12-31restructuringcompletedUSD 86 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges primarily related to employee severance and contractual obligations. No individual plans were significant.
2017-12-31restructuringcompletedUSD 86 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charges primarily related to employee severance and contractual obligations. No individually significant plans.
2017-12-31restructuringin_progressUSD 86,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressEmployee Severance [Member]USD 86,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-09-30restructuringin_progressUSD 7 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $7 million for the three months ended September 30, 2017; no employee counts disclosed. Restructuring reserve balance of $56 million as of September 30, 2017.
2017-09-30restructuringin_progressUSD 34 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $34 million for the nine months ended September 30, 2017; no employee counts disclosed.
2017-09-30restructuringin_progressUSD 34 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $7M for the three months and $34M for the nine months ended September 30, 2017; restructuring reserve accrued balance of $56M at quarter-end. No employee counts, announcement dates, or completion timelines disclosed.
2017-09-30restructuringin_progressUSD 34 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		AbbVie recorded restructuring charges of $34 million for the nine months ended September 30, 2017. No employee count was disclosed.
2017-09-30restructuringin_progressUSD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressUSD 11 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $11 million for the three months ended June 30, 2017; no employee counts disclosed. Restructuring reserve balance of $64 million as of June 30, 2017.
2017-06-30restructuringin_progressUSD 27 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $27 million for the six months ended June 30, 2017; no employee counts disclosed.
2017-06-30restructuringin_progressUSD 27 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $27M for the six months ended June 30, 2017 ($11M in Q2); reserve roll-forward from $87M to $64M. No employee counts, geographies, or completion dates disclosed.
2017-06-30restructuringin_progressUSD 27 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		AbbVie recorded restructuring charges of $27 million for the six months ended June 30, 2017. No employee count was disclosed.
2017-06-30restructuringin_progressUSD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressUSD 16 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $16 million for the quarter; reserve balance of $73 million at March 31, 2017. No employee counts disclosed.
2017-03-31restructuringin_progressUSD 16 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $16 million recorded for the three months ended March 31, 2017; reserve roll-forward disclosed (accrued balance $73 million at March 31, 2017) but no employee counts, geographies, or completion dates are disclosed.
2017-03-31restructuringin_progressUSD 16 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Filer recorded restructuring charges of $16 million for the three months ended March 31, 2017. No employee count or specific program details were disclosed in this footnote.
2017-03-31restructuringin_progressUSD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-12-31restructuringcompletedUSD 52 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Fiscal 2016 restructuring charges of $52 million, primarily employee severance and contractual obligations; no individually significant plans approved in the year. Restructuring reserve declined from $148 million at year-end 2015 to $87 million at year-end 2016 after $113 million of payments and other adjustments. No employee counts disclosed.
2016-12-31restructuringin_progressNot specifiedManufacturing, R&D, commercial infrastructure and administrative operationsUSD 52 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2016 restructuring charges of $52M, primarily severance and contractual obligations; filer states no individual plan was significant in 2016 and discloses no employee counts. Charges recorded in cost of products sold, R&D and SG&A; restructuring reserve balance was $87M at 2016-12-31
2016-12-31acquisition_additioncompleted2016-06-012016-06-01United StatesOncology (research and development)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Stemcentrx completed 2016-06-01 for total consideration of $6,426M; no headcount added through the acquisition is disclosed. Post-acquisition Stemcentrx operations contributed an operating loss of $165M in 2016
2016-12-31acquisition_additioncompleted2016-04-012016-04-01Germany / GlobalImmunology (research and development)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of risankizumab and BI 655064 rights completed 2016-04-01 for total consideration of $3,978M; no headcount added is disclosed
2016-12-31restructuringcompletedGlobalVariousUSD 52 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Restructuring charges of $52 million recorded in 2016, primarily related to employee severance and contractual obligations. No specific headcount affected disclosed.
2016-12-31acquisition_additioncompleted2016-06-012016-06-01GlobalBiotechnologybusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Stemcentrx, Inc. on June 1, 2016. Headcount not explicitly disclosed.
2016-12-31acquisition_additioncompleted2016-04-012016-04-01GlobalPharmaceuticalsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of rights to risankizumab (BI 655066) and BI 655064 from Boehringer Ingelheim on April 1, 2016. Headcount not explicitly disclosed.
2016-12-31restructuringcompletedUSD 52 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Restructuring charges of $52 million recorded in 2016, primarily related to employee severance and contractual obligations. No individual plans were significant.
2016-12-31restructuringin_progressUSD 52,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressEmployee Severance [Member]USD 52,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-09-30restructuringin_progressUSD 35 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $35M for nine months ended 2016-09-30 ($5M in Q3); reserve roll-forward from $148M to $90M. No employee counts, geographies, or completion dates disclosed.
2016-09-30acquisition_additioncompleted2016-06-01Oncologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		All outstanding equity of Stemcentrx acquired 2016-06-01; total consideration $6,426M. Headcount added not disclosed; post-acquisition operations ran an operating loss of $114M in the nine months.
2016-09-30restructuringin_progressUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Filer recorded restructuring charges of $5 million for the three months ended September 30, 2016. No employee count disclosed.
2016-09-30restructuringin_progressUSD 35 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Filer recorded restructuring charges of $35 million for the nine months ended September 30, 2016. No employee count disclosed.
2016-09-30restructuringin_progressUSD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30acquisition_additioncompleted2016-04-01GlobalResearch and Developmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired all rights to risankizumab (BI 655066) and BI 655064 from Boehringer Ingelheim; total consideration $4,375M ($595M cash upfront). No headcount added through the transaction is disclosed.
2016-06-30acquisition_additioncompleted2016-06-01Oncologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired Stemcentrx for total consideration of $6,153M (62.4M shares, $1,860M cash, $370M contingent consideration); added Rova-T and oncology pipeline. No employee count added is disclosed; $65M paid to accelerated-vesting option holders was recorded as post-acquisition stock-based compensation.
2016-06-30restructuringin_progressUSD 30 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $30M recorded in the six months ended June 30, 2016 with $68M of payments; reserve balance $110M at June 30, 2016. Filing states charges were not material and discloses no employee counts, geographies, or completion dates.
2016-06-30restructuringin_progressUSD 30 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring charges recorded for the six months ended June 30, 2016 were $30 million. Employee counts not disclosed.
2016-06-30restructuringin_progressUSD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Filer states Q1 2016 restructuring charges were not material; reserve rolled from $148M to $128M with $28M of payments. No employee counts, geographies, or completion dates disclosed.
2016-03-31acquisition_additionannounced2016-042016-06-30United StatesOncologysubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Stemcentrx for approximately $5.8B upfront (62.5M shares plus ~$2.0B cash), with up to $4.0B in milestones; expected to close in Q2 2016. No headcount associated with the transaction is disclosed.
2016-03-31restructuringin_progressUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring charges recorded for the three months ended March 31, 2016 were not material; $8 million in charges recorded against a reserve.
2016-03-31restructuringin_progressUSD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-12-31acquisition_additioncompleted2015-05-262015-05-26Oncology / hematologic oncology (IMBRUVICA)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition completed May 26, 2015 for approximately $20.8 billion ($12.4 billion cash plus about 128 million AbbVie shares valued at $8.4 billion), bringing the IMBRUVICA business into AbbVie. Both dates shown reflect the acquisition close, as the filing does not disclose the original agreement announcement date. The number of Pharmacyclics employees added through the combination is not quantified anywhere in the filing.
2015-12-31restructuringin_progressUSD 138 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2015 charges were primarily employee severance and contractual obligations, recorded across cost of products sold, R&D and SG&A based on affected employees or operations; no individually material restructuring plans were approved in 2015, so this reflects an aggregation of smaller actions. The reserve roll-forward shows $126 million of 2015 charges accrued, $100 million paid, and a $148 million accrued balance at December 31, 2015, indicating obligations remained outstanding at year-end. No headcount affected was disclosed.
2015-12-31restructuringin_progressNot specifiedManufacturing, R&D, commercial infrastructure and administrative operationsUSD 138 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2015 restructuring charges of $138 million, primarily employee severance and contractual obligations; no individual plan was individually material and no employees-affected count was disclosed. Charges recorded across cost of products sold, R&D and SG&A. Restructuring reserve balance was $148 million at 2015-12-31.
2015-12-31acquisition_additioncompleted2015-05-262015-05-26United StatesOncology (hematologic malignancies)USD 20,770 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Pharmacyclics, Inc. completed 2015-05-26 for approximately $20.8 billion total consideration ($12.4B cash, $8.4B equity); headcount added through the acquisition was not disclosed. Post-acquisition through 2015-12-31 the acquired business contributed $774 million of net revenues and a pre-tax operating loss of $519 million, including $346 million of acquisition-related compensation expense.
2015-12-31restructuringcompletedUSD 138 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Total restructuring charges of $138 million recorded in 2015, primarily related to employee severance and contractual obligations. Specific headcount affected is not disclosed.
2015-12-31restructuringcompletedUSD 138 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Restructuring charges recorded in 2015 were $138 million, primarily related to employee severance and contractual obligations. No plans were individually material.
2015-12-31acquisition_additioncompleted2015-05-26Oncologybusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Pharmacyclics, Inc. completed on May 26, 2015. Headcount added not explicitly disclosed.
2015-12-31restructuringin_progressUSD 138,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressRestructuring Plan2015 And Prior Years [Member]USD 126,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-09-30restructuringin_progressPrimarily SG&A, R&D, and cost of products soldUSD 22 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2015 restructuring charges of $22 million; nine-month charges of $50 million included $11 million asset impairments, remainder primarily employee severance. No employee counts disclosed.
2015-09-30restructuringin_progressUSD 50 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine months ended September 30, 2015 restructuring charges; includes $11 million asset impairments, remainder primarily employee severance. Reserve balance of $108 million at September 30, 2015 primarily relates to pre-2013 plans to realign worldwide manufacturing and selected commercial and R&D operations.
2015-09-30acquisition_additioncompleted2015-05-262015-05-26GlobalPharmaceutical products (oncology)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Pharmacyclics completed May 26, 2015 for approximately $20.8 billion; no employee/headcount addition figure disclosed in the filing
2015-09-30restructuringin_progressGlobalManufacturing, commercial and R&D operationsUSD 50 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $50 million for the nine months ended September 30, 2015 ($22 million for the quarter), primarily severance plus $11 million of asset impairments; no employees-affected count disclosed. Reserve balance $108 million at September 30, 2015; plans relate primarily to programs approved in years prior to 2013
2015-09-30restructuringin_progressWorldwideManufacturing, Commercial, and R&DUSD 22 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recorded for the three months ended Sept 30, 2015 primarily related to employee severance and asset impairments.
2015-09-30restructuringin_progressWorldwideManufacturing, Commercial, and R&DUSD 50 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recorded for the nine months ended Sept 30, 2015 included $11M asset impairments and remaining charges primarily related to employee severance.
2015-09-30restructuringin_progressUSD 39,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressAccelerated Depreciation Asset Impairments And Product Transfer Costs [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressCost Of Sales And Selling General And Administrative Expenses [Member]USD 50,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressWorldwideResearch and development; cost of products soldUSD 28 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $28M for the six months ended June 30, 2015 ($19M in Q2), including $11M of asset impairments; remainder primarily employee severance. No employee count, announcement date, or completion date disclosed. Reserve balance was $109M at June 30, 2015, largely for plans approved before 2013.
2015-06-30acquisition_additioncompleted2015-05-262015-05-26United StatesOncology (Pharmacyclics / IMBRUVICA)USD 20,770 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed May 26, 2015 for total consideration of approximately $20.8B; headcount added not disclosed. Post-acquisition period costs included $226M of acquisition-related compensation expense (retention), recorded in SG&A, R&D and cost of products sold.
2015-06-30restructuringin_progressWorldwideManufacturing, Commercial, R&DUSD 19 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges for three months ended June 30, 2015 included $11 million in asset impairments and remaining charges primarily related to employee severance. Reserve balance was $109 million as of June 30, 2015.
2015-06-30restructuringin_progressWorldwideManufacturing, Commercial, R&DUSD 28 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges for six months ended June 30, 2015 included $11 million in asset impairments and remaining charges primarily related to employee severance.
2015-06-30restructuringin_progressUSD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressAccelerated Depreciation Asset Impairments And Product Transfer Costs [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressCost Of Sales And Research And Development [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressWorldwide manufacturing operations; selected domestic and international commercial and R&D operationsUSD 9 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing plans approved in 2014 and prior years to reduce costs in conjunction with loss of exclusivity of certain products; Q1 2015 charges were cash costs primarily employee severance; restructuring reserve balance $119 million at March 31, 2015
2015-03-31restructuringin_progressWorldwideManufacturing operations; selected domestic and international commercial and R&D operationsUSD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plans approved in 2014 and prior years to realign operations ahead of loss of exclusivity; Q1 2015 charges were cash costs, primarily employee severance. Restructuring reserve: $122M at 2014-12-31, $9M charges, $(12)M payments, $119M at 2015-03-31. No employee counts or completion dates disclosed.
2015-03-31acquisition_additionannounced2015-03-042015-06-30United StatesOncology (Pharmacyclics, Inc. / IMBRUVICA)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire all outstanding shares at $261.25 per share (~58% cash / 42% stock), aggregate purchase price approximately $21 billion; expected to close in Q2 2015. No headcount disclosed for the target; $18B 364-day bridge loan entered 2015-03-27 with $59M financing-related costs recorded in interest expense.
2015-03-31restructuringin_progressWorldwideManufacturing, Commercial, R&DUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to employee severance. No specific headcount affected disclosed.
2015-03-31restructuringin_progressUSD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan2014 And Prior Years [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-12-31restructuringin_progressWorldwideManufacturing; commercial operations; R&DUSD 23 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year cost realignment of worldwide manufacturing and select commercial/R&D operations approved in 2014 and prior years, driven by loss of product exclusivity; no employee count disclosed. Of the 2014 charge, $16 million were cash costs primarily for employee severance and contractual obligations; year-end severance reserve of $122 million indicates the program remained active. FY2014 charges only — prior-year (2012/2013) program charges excluded per reporting-period rule.
2014-12-31restructuringin_progressWorldwideManufacturing operations and selected domestic/international commercial and R&D operationsUSD 23 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2014 activity only; charge primarily in cost of products sold with remainder in SG&A, including $16M of cash costs for severance and contractual obligations. Employees affected not disclosed. Restructuring reserve accrued balance was $122M at December 31, 2014, indicating the program remains open.
2014-12-31restructuringcompleted2014GlobalManufacturing, Commercial, R&DUSD 23 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges recorded in 2014 were $23 million, primarily in cost of products sold and SG&A. Included cash costs of $16 million for employee severance and contractual obligations. No specific employee count disclosed.
2014-12-31restructuringcompleted2014WorldwideManufacturing, Commercial, R&DUSD 23 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charges primarily related to employee severance and contractual obligations to realign operations.
2014-12-31restructuringin_progressRestructuring Plan2014 And Prior Years [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2014 And Prior Years [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-09-30restructuringin_progressWorldwideManufacturing operations; commercial and R&D operationsUSD 7 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing plans to realign worldwide manufacturing and selected commercial/R&D operations; Q3 2014 charges of $7 million primarily employee severance, recorded mainly in cost of goods sold. YTD charges were $16 million. No employee counts disclosed.
2014-09-30restructuringin_progressWorldwideManufacturing, commercial and R&D operationsUSD 16 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing program approved in 2013 and prior years to realign manufacturing and selected commercial/R&D operations; charges primarily employee severance recorded in cost of products sold. $7 million charged in Q3 2014; $16 million YTD 2014. Reserve roll-forward shows $11 million of 2014 charges, $60 million of payments, $142 million accrued at 2014-09-30. No employee counts or completion dates disclosed.
2014-09-30othercompleted2014-10-20United Kingdom / United StatesCorporateUSD 1,635 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Termination of proposed Shire combination; $1.635 billion break fee paid October 2014 to be recorded in SG&A in Q4 2014, plus $70 million capitalized financing costs to be expensed. No workforce impact quantified; included as material post-quarter corporate event with potential workforce implications.
2014-09-30restructuringin_progress2013-04-01WorldwideManufacturing, Commercial, R&DUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to employee severance for plans approved in 2013 and prior years to realign manufacturing, commercial, and R&D operations.
2014-09-30restructuringin_progress2013-04-01WorldwideManufacturing, Commercial, R&DUSD 16 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Year-to-date charges primarily related to employee severance for plans approved in 2013 and prior years.
2014-09-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan2013 And Prior Years [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressEmployee Severance [Member] / Restructuring Plan2013 And Prior Years [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progress2013-01-01WorldwideManufacturing, commercial and R&D operationsUSD 9 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plans approved in 2013 and prior years to realign worldwide manufacturing and selected commercial and R&D operations to reduce costs; six-month 2014 charges of $9 million primarily employee severance, recorded mainly in cost of goods sold. No employee counts disclosed.
2014-06-30restructuringin_progressWorldwideManufacturing, commercial and R&D operationsUSD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $9M for six months ended June 30, 2014 ($5M for the quarter), primarily employee severance in cost of products sold; plans approved in 2013 and prior years, so no announcement date in this filing. No employee counts disclosed. Restructuring reserve accrued balance $160M at June 30, 2014.
2014-06-30restructuringin_progressWorldwideManufacturing, Commercial, R&DUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to employee severance for plans approved in 2013 and prior years to realign manufacturing and commercial/R&D operations.
2014-06-30restructuringin_progressWorldwideManufacturing, Commercial, R&DUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD charges primarily related to employee severance for plans approved in 2013 and prior years.
2014-06-30restructuringin_progressThe entity's 2013 and prior years restructuring plans to realign its worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and research and development operations in order to reduce costs. / Cost of goods soldUSD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progressThe entity's 2013 and prior years restructuring plans to realign its worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and research and development operations in order to reduce costs. / Employee severance and contractual obligationsUSD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progress2013-01-01Commercial operationsUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2013-approved plan tied to loss of exclusivity of certain products; Q1 2014 charges of $2 million primarily in SG&A; restructuring reserve balance declined from $191 million to $170 million after $23 million of payments
2014-03-31restructuringin_progress2013-01-01WorldwideCommercial operationsUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program approved in 2013 to restructure commercial operations amid loss of exclusivity of certain products; $2M charged in Q1 2014, primarily in SG&A. No employee count disclosed. Restructuring reserve fell from $191M (2013-12-31) to $170M (2014-03-31) after $23M of payments.
2014-03-31restructuringin_progress2013-01-01GlobalCommercial operationsUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in 2013 to restructure commercial operations due to loss of exclusivity. $2 million charge recorded in Q1 2014. Employee count not disclosed.
2014-03-31restructuringin_progress2012-01-01GlobalManufacturing, Commercial, R&Drestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in 2012 to realign manufacturing and R&D. No new charges recorded in Q1 2014; only payments of $23 million from reserve.
2014-03-31restructuringin_progressRestructuring Plan 2012 and Prior Years [Member] / Employee severance and contractual obligationsUSD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-12-31restructuringin_progress2013Commercial operations (tied to loss/expected loss of exclusivity of certain products); charges recorded in SG&A, cost of products sold and R&DUSD 83 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plan approved in 2013 to restructure certain commercial operations in conjunction with loss/expected loss of product exclusivity. Of the $83 million total charge, cash costs of $76 million mainly related to employee severance and contractual obligations. Headcount affected and completion date not disclosed; status inferred from remaining restructuring reserve balance at year-end. Restructuring charges of the prior-year (2012) realignment program are excluded as comparative-period activity.
2013-12-31restructuringin_progressNot specifiedCommercial operationsUSD 83 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2013 program to restructure certain commercial operations tied to actual and expected loss of exclusivity; $83M total charges (primarily SG&A and cost of products sold, remainder in R&D), including $76M of cash costs mainly for severance. No employee count or completion date disclosed; restructuring reserve balance was $191M at year-end, including prior-year programs.
2013-12-31othercompleted2013-01-012013-12-31GlobalCorporate — separation from Abbott LaboratoriesUSD 254 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Separation-related expenses of $254M incurred in 2013 (legal, IT, regulatory fees, principally in SG&A); no headcount impact quantified. Included as context for standalone-company cost build-out rather than a headcount action.
2013-12-31restructuringcompleted2013GlobalCommercial Operations, R&DUSD 83 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges recorded in 2013 related to restructuring of certain commercial operations in conjunction with loss/expected loss of exclusivity. Includes $76 million in cash costs (severance/contractual). Employee count not explicitly disclosed.
2013-12-31restructuringcompleted2013GlobalCommercial operationsUSD 39 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Restructuring charges aggregating $39 million principally related to restructuring of certain commercial operations in conjunction with loss of exclusivity.
2013-12-31restructuringcompleted2013GlobalResearch and DevelopmentUSD 15 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		R&D expenses included restructuring charges of $15 million.
2013-12-31restructuringin_progress Restructuring Plan2013 And Prior YearsUSD 76,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Restructuring Plan2013 And Prior Years / Selling General And Administrative ExpensesUSD 83,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-09-30restructuringin_progressCommercial operationsUSD 11 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2013 plan to restructure certain commercial operations tied to loss of product exclusivity; Q3 charge of $11M primarily in SG&A, with remainder in R&D and cost of products sold; cash costs of $8M in the quarter mainly employee severance and contractual obligations
2013-09-30restructuringin_progressWorldwide manufacturing, commercial and R&D operationsUSD 75 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month 2013 charges of $75M under plans to realign worldwide manufacturing and selected commercial and R&D operations to reduce costs; cash costs of $68M mainly severance and contractual obligations; includes $23M Q1 reversal of a prior manufacturing-exit reserve
2013-09-30restructuringin_progress2013WorldwideManufacturing, commercial and research & development operationsUSD 75 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Programs approved in 2013 and prior years to realign worldwide manufacturing plus selected commercial and R&D operations; a further plan covering certain commercial operations tied to loss of exclusivity was approved in Q2 2013. Charge shown is the nine-month total ($11M in Q3); no employee counts disclosed. Includes $68M of cash costs (severance and contractual obligations) YTD and a $23M reversal of a prior-year reserve.
2013-09-30restructuringin_progress2013-04-01WorldwideManufacturing, Commercial, R&DUSD 11 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2013 charge of $11 million. YTD 2013 charge of $75 million. Includes cash costs of $8 million (Q3) and $68 million (YTD) mainly for employee severance and contractual obligations. Plans approved in 2013 and prior years to realign manufacturing, commercial, and R&D operations.
2013-09-30restructuringin_progress2013-04-01WorldwideCommercialrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		In Q2 2013, company approved plans to restructure certain commercial operations in conjunction with loss and expected loss of exclusivity of certain products. Included in the aggregate restructuring charges noted above.
2013-09-30restructuringin_progressUSD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringin_progress2013-04-01Commercial operationsUSD 55 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2013 plan to restructure certain commercial operations tied to loss and expected loss of exclusivity of certain products; charges primarily in SG&A with remainder in R&D and cost of products sold; cash costs of $51 million mainly for employee severance and contractual obligations; no employee count disclosed
2013-06-30restructuringin_progressWorldwide manufacturing and commercial/R&D operationsUSD 64 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Six-month 2013 charges of $64 million under plans to realign worldwide manufacturing and selected commercial and R&D operations to reduce costs; cash costs of $60 million mainly severance and contractual obligations; includes $23 million reversal in Q1 of a prior-year reserve for a manufacturing facility exit; no employee count disclosed
2013-06-30restructuringin_progress2013-04-01Not specifiedCommercial operations; remainder in R&D and cost of products soldUSD 64 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2013 approval to restructure certain commercial operations tied to loss of expected exclusivity of certain products; six-month charge $64M ($55M in Q2), of which $60M cash costs. Employee headcount affected not disclosed. Restructuring reserve balance $215M at 2013-06-30.
2013-06-30restructuringin_progress2013-04-01WorldwideCommercial operations, manufacturing, R&DUSD 55 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approved in Q2 2013 to restructure commercial operations due to loss of exclusivity. Charges primarily in SG&A. Cash costs of $51M mainly for employee severance.
2013-06-30restructuringin_progress2013-01-01WorldwideManufacturing, commercial, R&DUSD 60 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2013 charges for realignment of worldwide manufacturing and selected domestic/international commercial and R&D operations. Includes $23M reversal of prior year reserve.
2013-06-30restructuringin_progress Restructuring Plan2013 And Prior YearsUSD 55,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-31restructuringin_progressWorldwide manufacturing operations and selected domestic and international commercial and R&D operationsUSD 9 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2013 charge of ~$9 million for employee severance and contractual obligations ($7M in cost of products sold, $2M in SG&A); includes a $23 million reversal of a prior restructuring reserve related to a decision to exit a manufacturing facility. No employee counts disclosed.
2013-03-31restructuringin_progressWorldwideManufacturing, commercial and R&D operationsUSD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program approved in 2012 and prior years to realign worldwide manufacturing and selected commercial and R&D operations. Q1 2013 charge of $9M ($7M in cost of products sold, $2M in SG&A) for employee severance and contractual obligations; no employee count disclosed. Accrued balance moved from $193M to $178M, including a $23M reversal tied to a re-evaluated decision to exit a manufacturing facility.
2013-03-31restructuringin_progressWorldwideManufacturing, Commercial, R&DUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charge of approximately $9 million for employee severance and contractual obligations recorded in Q1 2013. Includes $23 million reversal of previously recorded reserve due to re-evaluation of decision to exit a manufacturing facility.
2013-03-31restructuringin_progress Restructuring Plan2012 And Prior YearsUSD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-12-31restructuringin_progress2012Worldwide (domestic and international)Worldwide manufacturing realignment and selected commercial and R&D operations; primarily exit from an R&D facilityUSD 177 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2012 charge was for employee severance and contractual obligations, primarily related to exit from an R&D facility ($169M classified in R&D, $8M in SG&A). An additional $69M was recorded in 2012 under these plans, primarily for accelerated depreciation. No employee-affected count disclosed. Payments of $74M in 2012 left a severance accrual of $193M at December 31, 2012, indicating the program remained in progress. Plans were approved in 2012 and prior years.
2012-12-31restructuringcompleted2010Various countriesSolvay sites and functions; AbbVie and Solvay commercial organizationsrestructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year plan initiated in 2010 following the Solvay acquisition, with an original employee severance charge of $147M (recorded 2010, not current year). Current fiscal year 2012 activity consisted solely of final payments of $20M; the severance accrual was fully settled to zero at December 31, 2012. Number of employees affected not disclosed.
2012-12-31restructuringin_progressResearch & DevelopmentUSD 177 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2012 charge of approximately $177 million for employee severance and contractual obligations, primarily tied to exiting an R&D facility; $169 million classified in R&D and $8 million in SG&A. Accrued balance of $193 million remained at December 31, 2012, indicating the program was not complete. Employees affected not disclosed.
2012-12-31restructuringin_progress2012-01-01GlobalManufacturing, Commercial, R&DUSD 177 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charge of $177 million recorded in 2012 for employee severance and contractual obligations, primarily related to exit from an R&D facility. Accrued balance at year-end was $193 million.
2012-12-31restructuringcompleted2012WorldwideManufacturing, Commercial, R&DUSD 177 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charge of $177 million for employee severance and contractual obligations, primarily related to exit from an R&D facility. Employee count not disclosed.
2012-12-31restructuringin_progressResearch and DevelopmentUSD 177 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2012 charge of approximately $177 million for employee severance and contractual obligations, primarily tied to exiting an R&D facility; $169 million classified in R&D and $8 million in SG&A. Accrued balance at December 31, 2012 was $193 million. Employees affected not disclosed; no announcement date or completion timeline given. Current-year activity only (excludes the separate 2011 charge of $160 million).
2012-12-31restructuringcompleted2012WorldwideManufacturing, Commercial, R&DUSD 177 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charge of approximately $177 million for employee severance and contractual obligations, primarily related to exit from an R&D facility. Employee count not disclosed.
2012-12-31restructuringcompleted2010Various countriesSolvay sites and functionsUSD 0 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2010 plan related to Solvay acquisition. Accrued balance was $0 at Dec 31, 2012, indicating completion. No new charges in 2012. Employee count not disclosed.